Dr. Yuankai Vincent Lin, MD, PhD

Dr. Lin practices at Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA.

Dr. Lin's NPI, 1831432988, was assigned on March 27, 2013. Dr. Lin graduated from Ross University School of Medicine in 2012. Dr. Lin holds California license A138455.

Dr. Lin's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center, at 1001 Potrero Avenue, San Francisco, CA 94110 in San Francisco County. The practice phone is (415) 206-8000.

Dr. Lin's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Dr. Lin to 6 more medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lin is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Lin's licenses on file in 4 states: California, Hawaii, Washington and Illinois.

Dmand AI lists lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Lin treats.

CMS data shows 43 Medicare services from Dr. Lin across 1 procedure code in 2024, all of them office visits, for 52 Medicare patients. Medicare paid $3,259 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 52 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 24 patients. 71% of them have cancer, and 67% have high cholesterol. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 71, with 42% women.

In 2024, Dr. Lin wrote 33 Medicare Part D claims for 15 patients. 45% of them were for generic drugs. CMS names the drug for 29 of them, across 2 drugs with 11 or more claims each, at $192,710 in total drug cost. In 2018, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Lin for performance year 2024, reported through an alternative payment model (APM). Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Lin, published from 2015 to 2022. 2021 was the busiest year, with 3. The most frequent topics are Antigens, CD34, Granulocyte Colony-Stimulating Factor and Hematopoietic Stem Cell Mobilization. Dr. Lin's most frequent co-authors are Nadim Mahmud, MD, MPH, MS, David J. Peace and Damiano Rondelli, MD.

CMS Open Payments shows 23 general payments to Dr. Lin from 13 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Genentech, Inc. paid the most, $653.

Dr. Lin graduated from Ross University School of Medicine in 2012.

Dr. Lin is in network with 9 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.